![Improved Enzyme Kinetics
PRXK110!vs.!Pulmozyme!
0.4
Commercial DNase I
Pulmozyme
PRX-110
PRX-110
V (µM/min)
0.3
0.2
0.1
0
0
20
40
[DNase Alert substrate] (µM)
DNase I
PRX-110
Pulmozyme
KM
(µM)
24.3
60.9
Vmax
(µM/min)
0.58
0.44
kcat
(sec-1)
6.24
4.76
kcat /KM
(sec-1µM -1)
0.26
0.08](https://image.slidesharecdn.com/protalixanalystdaypresentationjune202013v2-140211191137-phpapp01/85/Protalix-analyst-day-presentation-106-320.jpg)
![Biological Activity – IC50
% of control activity
100
PRX-107
Commercial
80
60
40
20
0
0.01
0.1
1
10
100
[AAT] (ug/ml)
Similar amounts of PRX-107 and commercial AAT reagent
needed to achieve 50% inhibition of Elastase](https://image.slidesharecdn.com/protalixanalystdaypresentationjune202013v2-140211191137-phpapp01/85/Protalix-analyst-day-presentation-115-320.jpg)
Protalix analyst day presentation
- 1. Analyst Event Thursday, June 20, 2013 The Westin New York Grand Central Hotel New York, NY
- 2. Note Regarding Forward-Looking Statements The presentations set forth herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements including, among others, statements regarding expectations as to regulatory approvals, market opportunity for the Company’s product candidates, goals as to product candidate development and timing of our clinical trials, are based on the Company s current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company s unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company s ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with planned facilities, intense competition, the uncertainty of patent and intellectual property protection, dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company s filings with the Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today s date. The Company undertakes no obligation to update or revise the information contained in this presentation whether as a result of new information, future events or circumstances or otherwise.
- 3. Agenda & Speakers Supply and Technology Transfer Agreement in Brazil Dr. David Aviezer, President and CEO, Protalix Biotherapeutics Commercial Update on Elelyso / Uplyso for Gaucher Disease Vera Wu, Global Asset Lead, Elelyso/Uplyso, Pfizer PRX-102 for Fabry Disease Dr. Gregory Pastores, Associate Professor, Neurology and Pediatrics, NYU School of Medicine Dr. Einat Almon, Senior Vice President, Product Development, Protalix Biotherapeutics Oral GCD for Gaucher Disease Dr. Yoseph Shaaltiel, Executive Vice President, Research and Development, Protalix Biotherapeutics Prof. Ari Zimran, Director, Gaucher Clinic, Shaare Zedek Medical Center, Jerusalem Preclinical Pipeline Candidates PRX-106, PRX-110 & PRX-107 Prof. Yaron Ilan, Director, Department of Medicine, Hebrew University Hadassah Medical Center Dr. Yoseph Shaaltiel, Executive Vice President, Research and Development, Protalix Biotherapeutics Q&A Session
- 4. Supply and Technology Transfer Agreement in Brazil Dr. David Aviezer, President and CEO, Protalix Biotherapeutics
- 5. Gaucher Market in Brazil ! ~600 patients treated ! ~US$65M market per year ! Additional untreated patients ! Enzyme therapy is fully paid for by the Brazilian Ministry of Health ! Currently two enzymes are available: ! ! Cerezyme Uplyso
- 6. Supply and Technology Transfer: Deal Description Stage 1 ! Protalix sells fully packaged vials to Fiocruz Stage 2 ! ! Protalix sells naked vials to Fiocruz which will be labeled and packed in Brazil Fiocruz set-ups and gets approval for a fill and finish facility Stage 3 ! ! Protalix sells drug substance to Fiocruz, which they will lyophilize, label and package into vials Fiocruz builds a validated manufacturing facility for UPLYSO Stage 4 ! ! ! ! Protalix establishes cell technology for Uplyso in Brazil Fiocruz conducts clinical trials with drug produced in their facility Fiocruz applies for approval of the facility and drug with ANVISA Protalix establishes cell bank for Uplyso in Brazil
- 7. Deal Description Cont… ! Throughout the entire agreement, Fiocruz will support and distribute Uplyso in Brazil ! Upon completing all four stages, Fiocruz will be able to produce Uplyso for the Brazil market on its own ! After the technology transfer is complete, Protalix will receive mid-single digit royalties on net sales by Fiocruz
- 8. Financial Benefits of the Deal ! Creates partnership with one of worlds growing economies ! Lucrative economics and steady cash flow for Protalix ! Ability to generate visible, meaningful revenues on limited operational expenses ! Relatively short penetration period into the market ! Eliminates the need to participate in bids ! Secures prices over a long period
- 9. Commercial Update on Elelyso / Uplyso for Gaucher Disease Vera Wu, Global Asset Lead, Elelyso/Uplyso, Pfizer
- 10. Elelyso / Uplyso Update U.S. Mexico Brazil Chile 11
- 11. Fabry disease Diagnosis and Management Gregory M. Pastores, MD NYU School of Medicine New York, NY
- 12. Fabry Disease Angiokeratoma corporis diffusum Johann Fabry (Germany) 1860-1930
- 13. Fabry disease Alpha-Galactosidase deficiency a-Galactosidase A Gb3 • Zebra bodies found in several types of cells: endothelial cells, pericytes, macrophages, fibroblasts, sweat gland cells, smooth muscle cells, glomerular epithelial cells, neuronal cells
- 14. Lyso-Gb3 Aerts JM, et al. Proc Natl Acad Sci U S A. 105(8):2812,2008
- 15. Fabry disease: Clinical expression Cardiomyopathy Arthytmia Obstructive airway disease Cerebrovascular events: TIA, Stroke Hearing loss Cornea Verticillata Gastrointestinal problems Renal insufficiency Acroparesthesia Angiokeratoma
- 16. Fabry disease: Clinical course Cardiac Problems Pain Renal Dysfunction Angiokeratoma CNS Problems Disease Course Abdominal Problems Renal Failure Death Age
- 17. Fabry disease: Renal pathology From storage to glomerulosclerosis
- 18. Kaplan-Meier analysis: Probability of developing chronic renal insufficiency, analyzed by residual α-Gal A activity Branton M et al. JASN 13:S139, 2007
- 19. ΔGFR on ERT in male FD patients, stratified according to baseline GFR. West M et al. JASN 20:1132,2009
- 20. Fabry nephropathy: Natural history Warnock D G et al. CJASN 5:371,2010
- 21. Rates of DGFR in patient with Fabry disease with or without ( ) ERT West, M. et al. J Am Soc Nephrol 20:1132-1139,2009
- 22. Fabry disease: Cardiovascular disease Perinuclear vacuoles (storage) and hypertrophy of cardiomyocytes Gb3 <2% Longitudinal strain curves; showing overall reduced deformation and markedly reduced systolic and postsystolic deformation in the basal (infero)-lateral segment
- 23. Fabry disease: Cardiovascular disease Concentric LVH (wall thickness 16 mm). Diastolic dysfunction with an abnormal mitral valve inflow pattern (C); impaired longitudinal systolic function on tissue Doppler imaging (D). Concentric LVH (wall thickness 20 mm) Late gadolinium enhancement, inferolateral wall from base to midventricle; sparing the endocardium.
- 24. Fabry disease: Cerebrovascular disease Cerebrovascular Lesions T1-weighted MRI Head CT CBF map
- 25. Fabry disease : Age adjusting severity scores Predicted FOS-MSSI Score Predicted FOS-MSSI Score Hughes DA, et al. Mol Genet Metab. 101(2-3):219,2010
- 26. Fabry disease Summary • Fabry disease is a complex multi-systemic disorder, associated with significant disease burden and shortened lifespan; affecting both males and female, and with symptom onset in childhood • There are currently two enzyme formulations, which indicate clinical benefit for certain patient groups, using different regimens • Interestingly, time on therapy appears to have a greater influence on mid term outcome (up to 10 years), rather than enzyme dose; although this needs to be examined in larger cohorts. Moreover, there is a need to stratify patients in according to disease severity at baseline, which appears to be a major determinant of outcome • Cardiac and cerebrovascular disease continue to be major drivers of morbidity, and renal insufficiency is progressive for those with advanced stages and significant proteinuria • Antibodies against the infused enzyme, appears to be neutralizing in some cases; based on increased substrate (GL3) excretion,; athough there is no evidence at this time of an adverse influence on outcome
- 27. PRX-102 for Fabry Disease Dr. Einat Almon, Senior Vice President, Product Development, Protalix Biotherapeutics
- 28. PRX-102 - A Plant Cell Expressed, Chemically Modified, Human α-Galactosidase for the Treatment of Fabry Disease
- 29. Fabry Disease Accumulation of Gb3 (α-Galactosidase-A substrate) in lysosomes Increased risk of stroke Hypertension and cardiomyopathy Renal insufficiency and renal failure Outcome: Poor quality of life - Death Source: Adopted from Najafian et al., Kidney Int. 2011
- 30. α-Galactosidase-A ! A non-covalently linked homo-dimer of 398aa each (~96 KDa) ! A lysosomal hydrolase that cleaves a terminal galactose from glycolipids/glycoproteins Gb3 α-Galactosidase-A
- 31. Fabry Disease Market ! Annual cost of treatment ~$250,000/patient ! Prevalence – between 1:40,000 – 1:120,000 ! Diagnosis rate is rapidly growing (CAGR = 12.8%) ! Market size (2012): ~$900M 2012 Fabry Market share Replagal $497M 56% Fabrazyme $388M 44%
- 32. Product Rationale Currently available treatment: ! Fabrazyme® (Genzyme) ! Replagal® (Shire) - Not approved in the US ! Both mimic the natural non-covalently bound homo-dimer ! Marketed products' half-life is a few minutes long ! Not all clinical parameters sufficiently addressed Protalix approach: Objective: ! Develop a Bio-Better enzyme with superior clinical effect Method: ! Generation of a stable dimer via covalent cross-linking
- 33. PRX-102 Product Description The chemical modification: ! Both protein sub-units are PEGylated , resulting in a covalently bound active and stable dimer Advantages: ! ! ! Improved stability Longer circulatory half life Enhanced uptake and activity in target organs PRX-102 properties can potentially lead to: ! ! Better clinical efficacy Different regimen
- 34. PRODUCT PROFILE
- 35. PRX-102 Characterization Western Blot Batch # Unmodified Protein Cross-linked Protein 1 2 3 SDS -PAGE 1 2 3
- 36. PRX-102 Enzyme Kinetics Reaction Rate (µM/min) Michaelis Menten Kinetics 3 2 1 PRX102 0 2 4 6 8 10 12 14 16 18 20 22 24 26 pNP-alpha-D-Galactpyranoside (mM) Sample ! KM (µM) ! Vmax (µM/ min)! Replagal® 4443 3.31 52.96 0.011! PRX-102 ! 3285 3.72 59.53 0.018 kcat (sec-1)! kcat /KM (sec-1* mM-1)! PRX-102 exhibits similar kinetic properties compared to commercial enzyme
- 37. PRX-102 Uptake into Fabry Cells PRX-102 localization in the lysosome of human Fabry patient fibroblast cells Anti-Gal (red) - PRX-102 PRX$102 Lamp 2 (green) - Lysosome lysosomal marker (Lamp2) Dapi (blue) - Nuclei Nuclei Merge
- 38. Glycosylation Pattern of PRX-102 Vs. Fabrazyme Glucose,Units 4 5 6 7 8 6 9 10 Mannose 8 Mannose N-acetylglucosamine 4 3 Xylose 2 Linkage position Fucose PRX102 α linkage M4 X β linkage Fc(3)M3X N -acetylglucosamine Xylose Fucose Unknown β linkage Sialic Acid αlinkage β linkage M4 Fc(3)M3 6 M8 Fc(3)XA1 Fluorescence 3 M3X M7 M5 A1X M9 Fabrazyme F(6)A2G2S1 + M5A1G1S1 A2G2S2 A2G2S1 A2G2S1 F(6)A1G1S1 F(6)A2G2S1 F(6)A3G3S1 F(6)A2G1S1 F(6)A2G2S2 A1G1S1 F(6)A1G1S1 A2G2 F(6)A3G3S3 M5 F(6)A3G3S2 60 70 80 90 Minutes 100 2 Linkage position M6 M7 8 4 110 120
- 40. Improved PK Prolonged circulatory half-life in Fabry mouse model Half-life (t½) Commercial - 13 min PRX-102 - 581 min
- 41. Bio-Distribution and Efficacy of PRX-102 in Fabry Mice Following Repeat Dosing Experiment Four injections, once every two weeks with 2mg/kg of either PRX-102 or placebo Gb3 clearance from target tissues following repeated administration of PRX-102
- 42. Improved In-vivo Activity PRX-102 Vs. Replagal Experiment Single injection of 2mg/kg of either PRX-102 or Replagal PRX-102 exhibits higher activity levels in target organs over time in Fabry mice
- 43. PRX-102 Toxicology Studies Design: ! Six month studies in two animal species : mice and cynomolgus monkeys ! GLP Tox and TK studies in both species: - Three doses (1X (2mg/kg), 5X and 20X of maximal clinical dose) - IV every two weeks Tox results: ! No systemic toxicity was observed in either species ! No safety concerns in monkeys at 20x dose "doses up to 2 mg/kg in patients should be well tolerated ! The data support long term clinical trials
- 45. Proposed Clinical Development Plan Phase 1/2 study Open Label, Dose Ranging ! Patients who complete the study will be offered the opportunity to enroll in an extension study Phase 3 Pivotal Study Double Blind, Active Controlled ! Patients who complete the study will be offered the opportunity to enroll in an extension study
- 46. Phase 1/2: ! ! 18 adult men and women patients (6/group), IV infusion once every two weeks ! Three doses (0.2mg/Kg,1mg/Kg, 2mg/Kg) ! Duration - 12 weeks (7 infusions, 3 months) Extension study: ! ! 18 patients, IV infusion once every two weeks, at same doses as in Phase 1/2 Duration - 38 weeks (20 infusions, 9 months) Study evaluation ! Gb3 in urine and blood, lyso-Gb3 in blood, pain, cardiac MRI ! Skin and kidney biopsies (after 6 months) Month = 0 3 Phase 1/2 12 6 Extension study
- 47. PRX-102 Clinical Development Status ! Ongoing phase I/II trial in Fabry patients (under IND) ! Current recruiting sites: ! Three sites in the United States ! One site in South America ! One site in the United Kingdom ! One site in Australia ! Additional sites pending
- 48. Oral GCD for Gaucher Disease Dr. Yoseph Shaaltiel, Executive Vice President, Research and Development, Protalix Biotherapeutics
- 49. PRX-112 - Oral Delivery of Plant Glucocerebrosidase (prGCD) for the Treatment of Gaucher Disease
- 50. Oral Delivery of Therapeutic Proteins The plant cell advantage: ! The concept: Plant cell wall (cellulose) serves as protective agent against the gastric environment ! Can serve as a natural vehicle for oral administration Three requirements for oral delivery of protein therapeutics: ! Protein must survive the gastric environment ! Protein must be released into the intestine from the cells ! Protein must be able to cross the intestinal wall and remain active
- 51. Ability to Survive the Gastric Environment Various proteins naturally encapsulated in plant cells were incubated in a “simulated gastric fluid” to asses the protective nature of the plant cell wall High pH!gradient! Low ! !! Time!(min)! !!!1!!!!!!!10!!!!30!!!!!!!1!!!!!!10!!!!30!!!!!!1!!!!!10!!!!!30!!!!!!!!!!!!!1!!!!!10!!!!30!!!!!!!1!!!!!10!!!30!!!!!1!!!!10!!!!!!30!!!!!!!!standard! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! ! ! !!!!!!!!! ! ! !!!!!!!!!!!!!!!!50!25!12.5 Standards!(ng/ml) Protein!! in!cells Purified!! protein
- 52. Cellular Assay That Mimics Crossing the Epithelial Barrier Protein is added to upper chamber Upper chamber medium: Simulated intestinal fluid CaCo-2 epithelial cells on membrane Lower chamber medium: HBSS pH 7.4 + 4% BSA Protein absorption is tested
- 53. Crossing the Epithelial Barrier (Caco-2 cell model) 2. Time lapse: Protein added to chamber. Transcytosis is measured after the indicated times at 37°C 1. Dose response: Protein added to chamber at different concentrations. Transcytosis is measured after 2 hours at 37°C 6 Protein activity in the basolateral chamber Protein activity in the basolateral chamber 7 5 4 3 2 1 0 X 2.5X 5X Protein added to the apical chamber 16 14 12 10 8 6 4 2 0 0 1 2 3 4 5 time (hours) 6 7 8
- 54. Timeline of Food Passing the Stomach Open stomach 4.5( 4( stomach!content!(gr)! Stomach 3.5( 3( 2.5( 2( 1.5( 1( 0.5( 0( 0( 5( 10( 15( @me!post!feeding! 20( 25(
- 56. 10 45 9 plasma liver 40 8 35 7 30 6 25 5 20 4 15 3 2 10 1 5 0 0 0 5 10 15 Time post feeding (hrs) 20 25 GCD activity in liver (percent change over baseline/gr) GCD activity in plasma (percent change over baseline/ml) prGCD Activity in Plasma and Target Organs
- 57. PK Experiments in Rodents Rats % addition of GCD activity Over baseline 60 50 40 30 20 10 0 0 2 4 6 8 10 12 Time post feeding (hours) ! Rats were fed lyophilized plant cells expressing prGCD ! Animals were assayed for the presence of prGCD in their plasma
- 58. % addition of GCD activity Over baseline PK experiments in Large Animals Pigs 60 50 40 30 20 10 0 0 1 2 3 4 5 6 Time post feeding (hours) 7 8 9 ! Animals were fed lyophilized plant cells expressing prGCD ! Animals were assayed for the presence of prGCD in the plasma for several hours post feeding
- 59. prGCD Feeding Experiment in Rats GCD activity mg/gr tissue Experiment plan: # Rats were fed with lyophilized carrot cells +/- prGCD; # Amounts of cell consumption were recorded # Feeding duration: twice with a six-hour interval # 2 hours following 2nd feeding, prGCD activity was measured in extracted organs 4( liver( 4( 3( spleen( 3( 2( 2( 1( 1( 0( $1( Control!(K)! (K)!AC! prGCD Active prGCD is found in target organs after feeding
- 60. prGCD Activity in Target Organs Rats liver 70 60 50 40 30 20 10 0 -10 -20 80 control feeding % GCD activity addition over the control % GCD activity addition over the control 80 Pigs liver 70 60 50 40 30 20 10 0 -10 -20 control feeding
- 61. Summary Animal studies of Oral prGCD demonstrate the following: # Absorbance # Active of GCD in the plasma (PK) prGCD detected in Gaucher target organs in-vivo
- 63. Disclosure! ! Receives consultancy fees and has options in Protalix Biotherapeutics and member of the Scientific Advisory Board; receives support from Genzyme/Sanofi for participation in the ICGG registry & from SHGT for GOS; honoraria; Pfizer and SHGT. ( (
- 64. Oral!delivery!of!therapeu@cs!proteins ! Long(Kme(goal(for(the(biopharmaceuKcal(industry( ! Currently(very(limited(success( ! Answers(a(desire(of(paKents(for(oral(treatment( ! A(safe,(non(invasive(method(of(delivery(of(protein(drugs( ! Allows(daily(intake(and(slow,(conKnuous(drug(delivery( ! High(paKent(compliance((
- 65. Oral!ERT!for!Gaucher!disease! ERT($(gold(standard(for(treatment(of(Gaucher(disease( 3(approved(ERTs( ! all(safe(and(efficient( ! all(administered(by(IV(infusion(every(2(weeks( Advantages(of(orally(administered(ERT(( ! well$established(therapy(mechanism( ! no(limitaKons(of(the(intravenous(administraKon(( ! conKnuous(enzyme(secreKon(to(blood(
- 66. PRXK112:!!Plant!expressed!GCD!for!oral!ERT! ! Edible(carrot(cells(expressing(recombinant((((((((((((((((((((((((((((((( human(glucocerebrosidase((prGCD)( ! Same(geneKcally(modified(carrot(plant(root(((((((((((((((((((((((((((((((((( cells(from(which(the(approved(drug(Elelyso™(( ! prGCD(expressed(in(carrot(cells((( as(a( ready(to(use (enzyme( ! Once(in(blood,(the(enzyme(is(expected(to(act(like(the(approved( IV(administered(Elelyso™( ! PRX$112(carrot(cells(are(prepared(as(a(drink(for( paKent( friendly (administraKon( !
- 83. PRXK112!Phase!1!study!status! ! Study(conducted(under(Israeli(MOH(and(IRBs(approval( ! Study(iniKated(in(Shaarei(Zedek((Jerusalem)((and(Rambam( (Haifa)(medical(centers( ! 1st(cohort((4(paKents)(–(completed( ! Expected(Study(compleKon(–(Q3(2013(
- 85. The(Future(
- 87. Forward!Looking!Statement! Please( be( advised( that( the( informaKon( and( projecKons( provided( in( this( presentaKon( may( include( forward$looking( statements( with( respect( to( plans,( projecKons( or( future( performance( of( PRX$106( and( Protalix,( the( occurrence( of( which( involves( certain( risks( and( uncertainKes( and( is( not( under(the(control(of(the(company,(including,(but(not(limited(to,(changes(in( regulatory( environment( and( improving( metabolic( homeostasis,( success( in( implemenKng( its( research,( development,( sales,( markeKng( and( manufacturing( plans,( protecKon( and( validity( of( patents( and( other( intellectual( property( rights( and( the( effect( of( compeKKon( by( other( companies.(( Disclosure! I( have( financial( relaKonships( with( Protalix( and( the( content( of( my( presentaKon(does(include(a(discussion(of(the(invesKgaKve(use(of(PRX$106.(
- 88. Oral!Immune!Therapy!Using!Plant!CellKexpressed! Recombinant!An@KTNF!Fusion!Protein!(PRXK106!)! PRXK106 Presented!to!the!! Gut!associated!lymphoid!@ssue! &!dendri@c!cells! Target!organs! • Bowel! • Pancreas! • Adipose!@ssue! • Liver! • Brain! Induc@on!of!regulatory!!! T!cells!(Tregs)!!in! mesenteric!lymph!nodes! A potential direct effect following absorption Modified(from:(Ilan(Y,(Immunology(Cell(Biology,(2009(
- 90. Orally!Administered!Plant!CellKexpressed!Recombinant! An@KTNF!fusion!protein!(PRXK106)!Alleviates!ConA! ImmuneKMediated!Hepa@@s ALT AST u/L 7000 6000 5000 4000 3000 2000 1000 0 * * &* &* &* * * p<0.02; relative to saline; & p< 0.0005, relative to negative control # p< 0.03, relative to negative control *
- 91. Serum&IFN*g&(pg/ml) Orally!Administered!Plant!CellKexpressed!Recombinant!An@K TNF!Fusion!Protein!(PRXK106)!Reduces!IFNγ!Serum!Levels 180 160 140 120 100 80 60 40 20 0 * *** &* #* * p<0.05; ** p<0.00001, relative to saline; & p< 0.004, relative to negative control # p< 0.02, relative to negative control
- 92. Orally!Administered!Plant!CellKexpressed!Recombinant! An@KTNF!Fusion!Protein!(PRXK106)!Alleviates!ConA! ImmuneKmediated!Hepa@@s ConA, Control (saline) ConA, Dex ConA, 0.5µg PRX-106 ConA, 0.5µg BY2 (negative cont)
- 97. Saline 0.5µg BY2- (Negative control) BY2+ 0.5µg PRX-106
- 100. Thank!you!
- 101. PRX-110 & PRX-107 Dr. Yoseph Shaaltiel, Executive Vice President, Research and Development, Protalix
- 103. DNase I ! ! ! Protein: Recombinant human deoxyribonuclease Indication: Cystic Fibrosis (CF) Protein function: Break down of excessive DNA in the accumulated mucus (sputum) in lungs of CF patients decreases viscosity of airway secretions ! Market (2012): 572M$ ! ! Marketed Product: Pulmozyme (Roche; Genentech) IP- Product patents expiration date: 2013
- 104. PRX-110 Product Description PRX-110 Advantages: ! Improved enzyme kinetics ! Less sensitive to inhibition by actin ! Improved ex-vivo efficacy PRX-110 properties can potentially lead to: ! Different regimen ! Lower cost
- 105. PRX-110 Characterization Pulmozyme MW PRX-110 MW µg: 10!!!!!!!5!!!!!2.5!!!!1.25!!!!!!!!!!!!10!!!!!5!!!!!2.5!!!!!1.25!!! SDS-PAGE K!175 K!80 K!58 K!46 K!30 K!25 K!17 K!7 Pulmozyme MW PRX-110 MW ng: 200!!!!100!!!50!!!!!!10!!! 200!!!100!!!50!!!!!10!!!!! Western blot Anti Pulmozyme Ab K!80 K!58 K!46 K!30 K!25 K!17 K!7
- 106. Improved Enzyme Kinetics PRXK110!vs.!Pulmozyme! 0.4 Commercial DNase I Pulmozyme PRX-110 PRX-110 V (µM/min) 0.3 0.2 0.1 0 0 20 40 [DNase Alert substrate] (µM) DNase I PRX-110 Pulmozyme KM (µM) 24.3 60.9 Vmax (µM/min) 0.58 0.44 kcat (sec-1) 6.24 4.76 kcat /KM (sec-1µM -1) 0.26 0.08
- 107. Reduced Inhibition of PRX-110 by human actin (IC50) PRXK110!vs.!Pulmozyme! 1.2 1 PRX-110 PRX-110 Commercial DNase I Pulmozyme ΔOD 630 0.8 0.6 0.4 0.2 0 0.1 1 10 100 actin (µg/ml) DNase!I! PRXK110! Pulmozyme! Ac@n!(ug/ml)! 1.8191!±!0.1003! 0.6870!±!0.0204!
- 108. Ex-vivo Efficacy Study on CF Patient’s Sputum PRXK110!vs.!Pulmozyme! 6! PRXK110!! Commercial!DNase!I! 20! 15! 10! 5! 0! 0! 2! 10! DNase!I!conc.!(ug/gr!sputum)! 20! Viscous!modulus!!(Pa)! Elas@c!modulus!!(Pa)! 25! PRXK110!! Commercial!DNase!I! 4! 2! 0! 0! 2! 10! 20! DNase!I!conc.!(ug/gr!sputum)! Improved Dose Dependent Effect of PRX-110 on the Rheological Properties of Sputum from CF Patients
- 109. N-linked Glycosylation of DNase I PRXK110!vs.!Pulmozyme ! GU values 5 6 7 8 9 10 11 12 Mannose N-acetylglucosamine 32% 49% PRX-110 Xylose Fucose 15% Hybrid Sialic Acid 4% Fluorescence α-linkage β-linkage 6 8 4 3 2 Linkage position Pulmozyme 60 70 80 90 100 Minutes 110 120 130
- 110. In Vivo Study - Inhalation of PRX-110 in Rats ! Nose-only aerosol inhalation exposure ! PRX-110 enzyme activity in animal lung after inhalation maintained substantial enzymatic activity
- 111. PRX-110 Development Status ! pre-IND meeting held with the FDA ! Toxicity studies planned for Q4/2013
- 112. PRX-107 – Plant Cell Recombinant Human Alpha1-antitrypsin (AAT) for the Treatment of Pulmonary Disorders AAT Trypsin
- 113. ! Main function: regulates AAT-dependent inflammatory response in the lungs ! Single-chain protein: 394aa, 52kDa ! Indication: Emphysema due to Hereditary AAT deficiency (AATD) ! Market (2012): est. ~$600M ! Marketed products are purified from plasma and administered IV ! No recombinant AAT approved
- 114. All marketed AAT products are plasma-derived ! ! Limited plasma supply Potential adventitious agents Protalix benefit: Recombinant AAT ! ! ! Easy scale up to meet demand No potential adventitious agents Lower production cost All marketed products are for IV use ! IV delivery results in only ~2% of the protein reaching the lungs PRX-107 goal: Inhalation delivery ! ! Directly to the lungs Better patient quality of life
- 115. Biological Activity – IC50 % of control activity 100 PRX-107 Commercial 80 60 40 20 0 0.01 0.1 1 10 100 [AAT] (ug/ml) Similar amounts of PRX-107 and commercial AAT reagent needed to achieve 50% inhibition of Elastase
- 116. In vivo Induced Emphysema Model Lm( healthy( Lm(–(mean(linear(intercept((diameter)( VL(–(lung(volume( Sa(–(alveolar(surface( Lm( emphysematous(
- 117. PRX-107 In-vivo Efficacy Study in Rats Group ID (10 rats/group) AAT (10mg/kg) Elastase dose (U/g BW) 1 2 3 4 5 mock PRX-107 mock PRX-107 Commercial 0 0 0.25 0.25 0.25 Post-mortem analyses: Lung collection and fixation Lung slide preparation Stereometry (quantitative histology)
- 118. Efficacy In-vivo Study Results ! ! ! Experiment - AAT Ability to rescue Elastase induced lung damage Comparison between PRX-107 and AAT (plasma derived reagent) The extent of the damage is measured by the mean alveolar volume p < 0.0001 (n=10) 4.5 p"<"0.0001"(n=10)" 4.0 mean alveolar volume p < 0.0001 (n=10) p < 0.0001 (n=10) 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 Induced Damage - - elastase elastase elastase Treatment - PRX-107 - PRX-107 Commercial
- 119. PRX-107 Development Status ! pre-IND meeting planned for H2 2013
- 120. Q&A Session